1AL-Hajj M, Wieha MS, Benito-Hernandez A, et al. Prospective iden- tification of tumorigenic breast cancer cells [ J ]. Proc Natl Acad Sci USA,2003,100(7) :3983-3988.
2Knoop AS, Kudsen H, Balslev E, et al. Retrospetive analysis of topoisomerase II a amplifications and deletions as predictive mark- ers in primary breast cancer patients randomly assigned to cyclo- phosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group [ J ]. J Clin Oneol, 2005,23 (30) : 7483-7490.
3Tanner M, Isola J, Wiklund T, et al. Topoisomerase 1I alpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER- 2/neu- amplified breast cancer: Scandinavian Breast Group Trial 9401 [J ]. J Clin Oncol, 2006,24(16) : 2428-2436.
4Harrison H, Farnie G, Howell SJ, et al. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor[J]. Can- cer Res,2010,70(2) :709-718.
5Guo J, Zhou J, Ying X, et al. Effects of stealth liposomal daunorubi- cin plus tamoxifen on the breast cancer and stem ceils [J]. J Pharm Sci,2010,13(2) : 136-151.
6Sheridan C, Kishimoto H, Fuchs RK, et al. CD44~/CD24- breast can- cer cells exhibit enhanced invasive properties : an early step neces- sary for metastasis [ J ]. Breast Cancer Res, 2006,8 (5) : R59.
7Sayed D, Abdellatif M. MicroRNAs in development and Physiol Rev, 2011,91 (3) : 827-887.
8Carthew RW, Sontheimer EJ. Origins and mechanisms and siRNAs[J ]. Cell, 2009,136(4) : 642-655. disease[J] of miRNAs.
9Shimono Y, Zabala M, Cho RW, et al. Downregulation of miRNA- 200c links breast cancer stem cells with normal stem cells [J]. Cell, 2009,138(3) :592-603.
10Iliopoulos D, Lindahl-Allen M, Polytarchou C, et al. Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression re- quired for the formation and maintenance of cancer stem ceils [J]. Mol Ce11,2010,39(5) :761-772.
